KRAS基因13号密码子突变与结直肠癌患者预后相关性的Meta分析  

Correlation between KRAS gene codon 13 mutation and prognosis in patients with colorectal cancer:a meta-analysis

作　　者：杨沔[1] 马浙平 陈彬[1] 彭涛[1] 俞甲子 YANG Mian;MA Zheping;CHEN Bin;PENG Tao;YU Jiazi(Department of Coloanorectal Surgery,Ningbo Medical Center Lihuili Hospital,Ningbo 315040,China)

机构地区：[1]宁波市医疗中心李惠利医院结肠肛肠外科,315000

出　　处：《浙江医学》2021年第12期1316-1319,1328,共5页Zhejiang Medical Journal

基　　金：宁波市自然科学基金(2018A610372)。

摘　　要：目的探讨KRAS基因13号密码子突变与结直肠癌(CRC)患者预后的相关性。方法检索PubMed、Web of Science、Cochrane Library、万方、中国知网等数据库从建库至2015年公开发表的关于KRAS基因13号密码子突变与CRC预后相关的文献,对13号密码子突变以及是否经抗表皮生长因子受体(EGFR)治疗对CRC患者总生存期(OS)的影响进行Meta分析,间接比较13号密码子突变与12号密码子突变对OS的影响。结果共纳入10篇文献4431例患者。13号密码子突变的CRC患者OS较短(HR=1.54,95%CI:1.16~2.04,P<0.05),其中未经过抗EGFR治疗患者OS较短(HR=1.76,95%CI:1.24~2.50,P<0.05);而经过抗EGFR治疗患者与野生型患者OS比较,差异无统计学意义(HR=1.56,95%CI:0.97~2.51,P>0.05)。13号密码子突变与12号密码子突变对CRC患者OS的影响比较,差异无统计学意义(HR=0.86,95%CI:0.65~1.14,P>0.05)。结论KRAS基因13号密码子突变的CRC患者OS较短,经抗EGFR治疗后与野生型患者OS相似。13号密码子突变型与12号密码子突变型患者在OS上差异不明显。Objective To investigate the correlation between KRAS gene codon 13 mutation and prognosis in patients with colorectal cancer(CRC)by Meta-analysis.Methods Literature on the correlation between KRAS gene codon 13 mutation and prognosis of CRC was retrieved from PubMed,Web of Science,Cochrane Library,Wanfang,CNKI and other databases published from incipience to 2015.Meta-analysis was performed to investigate the correlation between KRAS gene codon 13 mutation and overall survival(OS)of CRC patients;and the effect of anti-epidermal growth factor receptor(EGFR)treatment on the prognosis of patients.Results Ten studies involving 4431 patients were included in the analysis.CRC patients with codon 13 mutation had a shorter OS(HR=1.54,95%CI:1.16-2.04,P<0.05),and those without anti-EGFR treatment had a worse OS(HR=1.76,95%CI:1.24-2.50,P<0.05).However,there was no significant difference in OS between patients treated with anti-EGFR and those with wild-type KRAS gene(HR=1.56,95%CI:0.98-2.51,P>0.05).There was no significant difference in the effect on OS between CRC patients with codon 13 mutation and those with codon 12 mutation(HR=0.86,95%CI:0.65-1.14,P>0.05).Conclusion CRC patients with KRAS codon 13 mutation have a shorter OS,however,the OS after anti-EGFR treatment is similar to that of wild-type patients.There is no significant difference in OS between patients with codon 13 mutation and codon 12 mutation.

关 键 词：结直肠癌 预后 KRAS基因 13号密码子 基因突变 META分析 

分 类 号：R735.34[医药卫生—肿瘤]